Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anjianning (adalimumab biosimilar) in pediatric severe plaque psoriasis (China real-world, single-arm)
ChiCTR2500104734Phase 4Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anjianning in psoriasis, sponsored by First Hospital of China Medical University. Primary endpoint: Percentage of Subjects Achieving PASI75 at Week 16. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
anjianning
03
Conditions
psoriasis
Beyond the preview
Go deeper on ChiCTR2500104734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104734.